Patents by Inventor Francois Radvanyi
Francois Radvanyi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11536724Abstract: The invention relates to a collection of signature peptides representing at least 10 proteins for use in cancer diagnosis and/or prognosis, to an artificial protein comprising signature peptides representing at least 10 proteins and to a nucleic acid construct encoding for such an artificial protein. The invention further relates to a collection of at least 10 proteins for use in cancer diagnosis and/or prognosis. Additionally, the invention relates to a method for cancer diagnosis and/or prognosis comprising the step of analyzing at least 10 proteins in a urine sample of a subject. Finally, the invention relates to an immunoassay product comprising antibodies for detecting at least 10 proteins.Type: GrantFiled: December 23, 2016Date of Patent: December 27, 2022Assignees: POLYQUANT GMBH, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS, LUXEMBOURG INSTITUTE OF HEALTH, INSTITUT CURIE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III, CNIOInventors: Jerome Garin, Christophe Masselon, Antonia Vlahou, Manousos Makrydakis, Ieronimos Zoidakis, Bruno Domon, Elodie Duriez, Aurelie Kamoun, Francois Radvanyi, Yves Allory, Nuria Malats Riera, Mirari Marquez Cid, Magali Court
-
Publication number: 20210123914Abstract: The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown in Table, and comparing the amount of said at least one biomarker with a reference amount for said at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted. The present invention also contemplates a method for identifying a subject being in need of a further bladder cancer therapy. Encompassed are, furthermore, diagnostic devices and kits for carrying out said methods.Type: ApplicationFiled: September 25, 2020Publication date: April 29, 2021Applicants: Deutsches Krebsforschungszentrum, Institut CurieInventors: Christoph SCHRÖDER, Harish SRINIVASAN, Jörg HOHEISEL, François RADVANYI
-
Patent number: 10809261Abstract: The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown in Table, and comparing the amount of said at least one biomarker with a reference amount for said at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted. The present invention also contemplates a method for identifying a subject being in need of a further bladder cancer therapy. Encompassed are, furthermore, diagnostic devices and kits for carrying out said methods.Type: GrantFiled: May 8, 2017Date of Patent: October 20, 2020Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, INSTITUT CURIEInventors: Christoph Schröder, Harish Srinivasan, Jörg Hoheisel, François Radvanyi
-
Publication number: 20180372754Abstract: The invention relates to a collection of signature peptides representing at least 10 proteins for use in cancer diagnosis and/or prognosis, to an artificial protein comprising signature peptides representing at least 10 proteins and to a nucleic acid construct encoding for such an artificial protein. The invention further relates to a collection of at least 10 proteins for use in cancer diagnosis and/or prognosis. Additionally, the invention relates to a method for cancer diagnosis and/or prognosis comprising the step of analyzing at least 10 proteins in a urine sample of a subject. Finally, the invention relates to an immunoassay product comprising antibodies for detecting at least 10 proteins.Type: ApplicationFiled: December 23, 2016Publication date: December 27, 2018Inventors: Jerome GARIN, Christophe MASSELON, Antonia VLAHOU, Manousos MAKRYDAKIS, Ieronimos ZOIDAKIS, Bruno DOMON, Elodie DURIEZ, Aurelie KAMOUN, Francois RADVANYI, Yves ALLORY, Nuria MALATS RIERA, Mirari MARQUEZ CID, Magali COURT
-
Publication number: 20180105596Abstract: The present invention relates to antibodies, in particular human or humanized antibodies, that bind to the extracellular domain of human Tyro3 receptor, in particular to the immunoglobulin-like domain Ig-1, and reduce or inhibit the binding of human Gas6 to said receptor. The invention also relates to the uses of these antibodies in the diagnosis, prevention or treatment of hyperproliferative or infectious diseases.Type: ApplicationFiled: April 15, 2016Publication date: April 19, 2018Inventors: VANESSA DUONG, THIERRY MENGUY, HELENE HAEGEL, ISABELLE BERNARD-PIERROT, FLORENT DUFOUR, FRANCOIS RADVANYI
-
Publication number: 20170336414Abstract: The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown in Table, and comparing the amount of said at least one biomarker with a reference amount for said at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted. The present invention also contemplates a method for identifying a subject being in need of a further bladder cancer therapy. Encompassed are, furthermore, diagnostic devices and kits for carrying out said methods.Type: ApplicationFiled: May 8, 2017Publication date: November 23, 2017Applicants: Deutsches Krebsforschungszentrum, Institut CurieInventors: Christoph SCHRODER, Harish SRINIVASAN, Jõrg HOHEISEL, François RADVANYI
-
Patent number: 9678075Abstract: The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown in Table, and comparing the amount of said at least one biomarker with a reference amount for said at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted. The present invention also contemplates a method for identifying a subject being in need of a further bladder cancer therapy. Encompassed are, furthermore, diagnostic devices and kits for carrying out said methods.Type: GrantFiled: June 8, 2012Date of Patent: June 13, 2017Assignees: Deutsches Krebsforschungszentrum, Institut CurieInventors: Christoph Schröder, Harish Srinivasan, Jörg Hoheisel, François Radvanyi
-
Patent number: 9233144Abstract: The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer.Type: GrantFiled: September 18, 2009Date of Patent: January 12, 2016Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, UNIVERSITE PARIS-EST CRETEIL VAL DE MARNEInventors: Isabelle Bernard-Pierrot, Francois Radvanyi, Yves Allory, Nicolas Stransky
-
Publication number: 20140193927Abstract: The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown in Table, and comparing the amount of said at least one biomarker with a reference amount for said at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted. The present invention also contemplates a method for identifying a subject being in need of a further bladder cancer therapy. Encompassed are, furthermore, diagnostic devices and kits for carrying out said methods.Type: ApplicationFiled: June 8, 2012Publication date: July 10, 2014Inventors: Christoph Schröder, Harish Srinivasan, Jörg Hiheisel, François Radvanyi
-
Publication number: 20130059303Abstract: The present invention provides methods for predicting clinical outcome and for providing information for determining follow-up strategy of a subject affected with a non-muscle invasive bladder cancer, as well as a method for selecting a subject affected with a non-muscle invasive bladder cancer for an anti-tumoral therapy. The present invention also provides kits for implementing these methods.Type: ApplicationFiled: September 6, 2012Publication date: March 7, 2013Inventor: FRANCOIS RADVANYI
-
Publication number: 20120282167Abstract: The present invention provides a method for determining the RES phenotype in a tumor. The present invention further provides a method for predicting the sensitivity of a tumor to an epigenetic treatment, the method comprising determining the RES phenotype in said tumor, the presence of the RES phenotype in a tumor being indicative of a tumor sensitive to an epigenetic therapy. The present invention also provides a method for diagnosing an aggressive tumor and for selecting a patient affected with a tumor for an epigenetic therapy.Type: ApplicationFiled: August 9, 2010Publication date: November 8, 2012Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE, UNIVERSITE PARIS-SUD 11Inventors: Céline Vallot, Francois Radvanyi, Nicolas Stransky, Yves Allory
-
Publication number: 20120034167Abstract: The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer.Type: ApplicationFiled: September 18, 2009Publication date: February 9, 2012Applicants: INSTITUT CURIE, UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Isabelle Bernard-Pierrot, Francois Radvanyi, Yves Allory, Nicolas Stransky
-
Publication number: 20100166737Abstract: The present invention concerns methods and compositions for treating bladder carcinoma by p38 inhibitors.Type: ApplicationFiled: May 16, 2008Publication date: July 1, 2010Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, UNIVERSITE PARIS 12Inventors: Isabelle Bernard-Pierrot, Francois Radvanyi, Yves Allory